Climb Bio Inc. has announced upcoming presentations of new data at the 2025 American Society of Nephrology (ASN) Kidney Week, scheduled for November 6-9, 2025, in Houston, Texas. The company will present preclinical data on CLYM116, a novel Fc-engineered anti-APRIL monoclonal antibody in development for IgA nephropathy (IgAN). The data highlight favorable pharmacokinetic and pharmacodynamic properties, including enhanced antibody recycling and sustained reduction of IgA in preclinical models. Additionally, Climb Bio has published long-term follow-up clinical results from its Phase 1b trial of budoprutug, an anti-CD19 monoclonal antibody, in primary membranous nephropathy (pMN). The results indicate long-term control of proteinuria for up to three years after initial dosing, with no further immunosuppressive treatment required in most patients studied. No clinically significant treatment-related adverse events were reported. The abstracts for both programs are now available on the ASN Kidney Week conference website, and the results will be formally presented at the conference.